Please login to the form below

Not currently logged in
Email:
Password:

stomach cancer

This page shows the latest stomach cancer news and features for those working in and with pharma, biotech and healthcare.

Vyriad inks immunotherapy alliance with Merck/Pfizer

Vyriad inks immunotherapy alliance with Merck/Pfizer

Oncolytic viruses are engineered to selectively replicate within and destroy cancer cells while simultaneously augmenting anti-tumour immunity, and are generally injected directly into tumour sites. ... cell lung cancer and also had a knockback in

Latest news

  • Merck/Pfizer’s cancer immunotherapy latecomer hits a snag Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

    use into the much bigger non-small cell lung cancer (NSCLC) category are looking shaky after the failure of the JAVELIN Lung 200 study. ... It’s not the first setback for Bavencio, which failed a trial in third-line stomach cancer treatment last year,

  • Merck and Pfizer’s PD-L1 drug Bavencio flunks phase III trial Merck and Pfizer’s PD-L1 drug Bavencio flunks phase III trial

    Fails late-stage stomach cancer study. Already playing catch-up in the immuno-oncology market, Merck KGaA and Pfizer’s hopes for their PD-L1 inhibitor Bavencio just took a knock ... These include Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers

  • Mylan gets first biosimilar Herceptin OK from FDA Mylan gets first biosimilar Herceptin OK from FDA

    The biosimilar – developed by Mylan and Biocon and called Ogivri (trastuzumab-dkst) – has been approved by the FDA for HER2-positive breast or metastatic stomach cancer, the same indications as Herceptin ... This is especially important when it comes

  • Keytruda adds stomach cancer to growing list of US approvals Keytruda adds stomach cancer to growing list of US approvals

    an FDA green light for use of the drug in stomach cancer. ... The company notes that Keytruda is the first PD-1 inhibitor to be approved for stomach cancer in the US and will be used for patients who have disease progression despite

  • Lilly pitches Cyramza at bladder cancer Lilly pitches Cyramza at bladder cancer

    that are starting to transform the treatment of bladder cancer after decades of stagnation. ... It's still posting good growth overall however, bringing in $614m last year and up 60% thanks to big gains in Japan in the stomach cancer category.

More from news
Approximately 4 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Country report: The healthcare market in China Country report: The healthcare market in China

    Leading public health issues include HIV/AIDS, cancer (stomach, lung, liver, cervical, breast) and heart diseases. ... Approximately 400, 000 patients are newly diagnosed with stomach cancer annually, with a rising prevalence in the number of younger

  • Country report: The healthcare market in Japan Country report: The healthcare market in Japan

    3. Coronary heart disease. 4. Lung cancer. 5. Stomach cancer. 6. ... The largest therapeutic category is Renin-angiotensin system agents (antihypertensive), followed by anti-neoplastics (cancer drugs).  .

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics